Breast Cancer:@0.781548:0.035749:0.914554:0.035749:0.914554:0.019993:0.781548:0.019993:0.011045:0.005717:0.012508:0.013143:0.007466:0.006523:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
51:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
hormonal blockade with tamoxifen or :@0.084848:0.096166:0.481113:0.096166:0.481113:0.080410:0.084848:0.080410:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.013143:0.003848:0.015048:0.013123:0.003848:0.012604:0.012450:0.009660:0.013143:0.013181:0.012508:0.015048:0.015990:0.003848:0.006523:0.011738:0.015048:0.006523:0.013143:0.018049:0.012604:0.009236:0.003848:0.006042:0.012508:0.011738:0.015048:0.012604:0.005792:0.005330
aromatase inhibitors. Tamoxifen is used in :@0.084848:0.112451:0.481107:0.112451:0.481107:0.096695:0.084848:0.096695:0.013143:0.005715:0.012604:0.018049:0.013143:0.006523:0.013143:0.007466:0.012508:0.007331:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005330:0.007331:0.007197:0.013143:0.018049:0.012604:0.009236:0.003848:0.006042:0.012508:0.011738:0.007331:0.003848:0.007466:0.007331:0.011699:0.007466:0.012508:0.013181:0.007331:0.003848:0.011738:0.005330
premenopausal patients with or without :@0.084848:0.128736:0.481088:0.128736:0.481088:0.112980:0.084848:0.112980:0.013123:0.005715:0.012508:0.018049:0.012508:0.011738:0.012604:0.013123:0.013143:0.011699:0.007466:0.013143:0.003848:0.010487:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.010487:0.015990:0.003848:0.006523:0.011738:0.010487:0.012604:0.005792:0.010487:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.005330
luteinising hormone-releasing hormone :@0.084848:0.145021:0.481086:0.145021:0.481086:0.129265:0.084848:0.129265:0.003848:0.011699:0.006523:0.012508:0.003848:0.011738:0.003848:0.007466:0.003848:0.011738:0.012950:0.019839:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.012508:0.006388:0.005703:0.012508:0.003848:0.012508:0.013143:0.007466:0.003848:0.011738:0.012950:0.019839:0.011738:0.012604:0.006315:0.018049:0.012604:0.011738:0.012508:0.005330
agonists (LHRH), and aromatase inhibitors :@0.084848:0.161306:0.481082:0.161306:0.481082:0.145550:0.084848:0.145550:0.013143:0.012950:0.012604:0.011738:0.003848:0.007466:0.006523:0.007466:0.006975:0.007100:0.008890:0.013143:0.011680:0.013143:0.007100:0.005330:0.006972:0.013143:0.011738:0.013181:0.006973:0.013143:0.005715:0.012604:0.018049:0.013143:0.006523:0.013143:0.007466:0.012508:0.006975:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005330
are mainly indicated for postmenopausal :@0.084848:0.177591:0.481078:0.177591:0.481078:0.161835:0.084848:0.161835:0.013143:0.005715:0.012508:0.006677:0.018049:0.013143:0.003848:0.011738:0.003848:0.010314:0.006677:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.006677:0.006042:0.012604:0.005792:0.006667:0.013123:0.012604:0.007466:0.006523:0.018049:0.012508:0.011738:0.012604:0.013123:0.013143:0.011699:0.007466:0.013143:0.003848:0.005330
women. Aromatase inhibitors can also be :@0.084848:0.193876:0.481103:0.193876:0.481103:0.178120:0.084848:0.178120:0.015990:0.012604:0.018049:0.012508:0.011738:0.005330:0.006142:0.014239:0.005707:0.012604:0.018049:0.013143:0.006523:0.013143:0.007466:0.012508:0.006158:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.006158:0.012450:0.013143:0.011738:0.006158:0.013143:0.003848:0.007466:0.012604:0.006158:0.013123:0.012508:0.005330
used in high-risk premenopausal women :@0.084848:0.210452:0.481088:0.210452:0.481088:0.194696:0.084848:0.194696:0.011699:0.007466:0.012508:0.013181:0.009371:0.003848:0.011738:0.009371:0.011738:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660:0.009371:0.013123:0.005715:0.012508:0.018049:0.012508:0.011738:0.012604:0.013123:0.013143:0.011699:0.007466:0.013143:0.003848:0.009371:0.015990:0.012604:0.018049:0.012508:0.011738:0.005330
combined with an LHRH agonist.:@0.084848:0.227029:0.387108:0.227029:0.387108:0.211273:0.084848:0.211273:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.012508:0.013181:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013143:0.011738:0.005330:0.008890:0.013143:0.011680:0.013143:0.005330:0.013143:0.012950:0.012604:0.011738:0.003848:0.007466:0.006523:0.005330
9:@0.387089:0.221371:0.393304:0.221371:0.393304:0.212185:0.387089:0.212185:0.006215
In this instance, high-risk disease includes :@0.103030:0.243563:0.481097:0.243563:0.481097:0.227807:0.103030:0.227807:0.004349:0.011738:0.004407:0.006523:0.011738:0.003848:0.007466:0.004407:0.003848:0.011738:0.007466:0.006523:0.013143:0.011738:0.012450:0.012508:0.005330:0.004407:0.011738:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660:0.004407:0.013181:0.003848:0.007466:0.012508:0.013143:0.007478:0.012508:0.004407:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007466:0.005330
node-positive patients,  those  who  were :@0.084846:0.260139:0.481103:0.260139:0.481103:0.244383:0.084846:0.244383:0.011738:0.012604:0.013181:0.012508:0.006388:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.011468:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005330:0.006127:0.006523:0.011738:0.012604:0.007466:0.012508:0.005330:0.006129:0.015990:0.011738:0.012604:0.005330:0.006121:0.015990:0.012508:0.005713:0.012508:0.005330
deemed to require adjuvant chemother-:@0.084846:0.276715:0.475756:0.276715:0.475756:0.260959:0.084846:0.260959:0.013181:0.012508:0.012508:0.018049:0.012508:0.013181:0.007620:0.006523:0.012604:0.007610:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.007620:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.007620:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005765:0.006388
apy, high grade and presence of lympho-:@0.084846:0.293291:0.475756:0.293291:0.475756:0.277536:0.084846:0.277536:0.013143:0.013123:0.010314:0.005330:0.005061:0.011738:0.003848:0.012950:0.011738:0.005061:0.012950:0.005792:0.013143:0.013181:0.012508:0.005061:0.013143:0.011738:0.013181:0.005061:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.005061:0.012604:0.006042:0.005061:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.006388
vascular invasion.:@0.084846:0.309868:0.248753:0.309868:0.248753:0.294112:0.084846:0.294112:0.010660:0.013143:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.005330:0.003848:0.011738:0.010660:0.013143:0.007466:0.003848:0.012604:0.011738:0.005330
Clinical trials have also supported con-:@0.103030:0.326444:0.475763:0.326444:0.475763:0.310688:0.103030:0.310688:0.015644:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.007889:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.007889:0.011738:0.013143:0.010660:0.012508:0.007889:0.013143:0.003848:0.007466:0.012604:0.007889:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.012508:0.013181:0.007878:0.012450:0.012604:0.011738:0.006388
sideration  for  10  years  compared  to  five :@0.084846:0.343020:0.481084:0.343020:0.481084:0.327264:0.084846:0.327264:0.007466:0.003848:0.013181:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.003477:0.006042:0.012604:0.005792:0.005330:0.003469:0.010660:0.010660:0.005330:0.003483:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.003479:0.012450:0.012604:0.018049:0.013123:0.013143:0.005715:0.012508:0.013181:0.005330:0.003477:0.006523:0.012604:0.005330:0.003471:0.004686:0.004686:0.010660:0.012508:0.005330
years of hormonal blockade. This is on the :@0.084846:0.359596:0.481084:0.359596:0.481084:0.343840:0.084846:0.343840:0.010314:0.012508:0.013143:0.005792:0.007466:0.005638:0.012604:0.006042:0.005638:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.013143:0.003848:0.005638:0.013123:0.003848:0.012604:0.012450:0.009660:0.013143:0.013181:0.012508:0.005330:0.005638:0.008197:0.011738:0.003848:0.007466:0.005638:0.003848:0.007466:0.005650:0.012604:0.011738:0.005638:0.006523:0.011738:0.012508:0.005330
basis of an increased risk of recurrence up :@0.084846:0.376172:0.481099:0.376172:0.481099:0.360416:0.084846:0.360416:0.013123:0.013143:0.007466:0.003848:0.007466:0.005226:0.012604:0.006042:0.005205:0.013143:0.011738:0.005215:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.013181:0.005215:0.005792:0.003848:0.007466:0.009660:0.005215:0.012604:0.006042:0.005215:0.005711:0.012508:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.012450:0.012508:0.005203:0.011699:0.013123:0.005330
to  15  years  following  completion  of  five :@0.084846:0.392748:0.481090:0.392748:0.481090:0.376992:0.084846:0.376992:0.006523:0.012604:0.005330:0.004545:0.010660:0.010660:0.005330:0.004560:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.004555:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.004555:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.003848:0.012604:0.011738:0.005330:0.004547:0.012604:0.006042:0.005330:0.004547:0.004686:0.004686:0.010660:0.012508:0.005330
years of adjuvant endocrine therapy.  :@0.084846:0.409325:0.481087:0.409298:0.481087:0.393542:0.084846:0.393569:0.010314:0.012508:0.013143:0.005792:0.007466:0.012950:0.012604:0.006042:0.012950:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.012950:0.012508:0.011738:0.013181:0.012604:0.012450:0.005792:0.003848:0.011726:0.012508:0.012950:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.012424:0.406363
10:@0.463323:0.403679:0.475753:0.403679:0.475753:0.394493:0.463323:0.394493:0.006215:0.006215
Two large trials have demonstrated the :@0.084848:0.425874:0.481120:0.425874:0.481120:0.410118:0.084848:0.410118:0.008324:0.015990:0.012604:0.010622:0.003848:0.013143:0.005813:0.012950:0.012508:0.010622:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.010622:0.011738:0.013143:0.010660:0.012508:0.010622:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.010622:0.006523:0.011738:0.012508:0.005330
superiority of 10 years:@0.084848:0.442450:0.287470:0.442450:0.287470:0.426694:0.084848:0.426694:0.007466:0.011699:0.013123:0.012508:0.005792:0.003848:0.012604:0.005792:0.003848:0.006523:0.010314:0.006639:0.012604:0.006042:0.006639:0.010660:0.010660:0.006639:0.010314:0.012508:0.013143:0.005792:0.007466
 vs :@0.287470:0.442450:0.317565:0.442450:0.317565:0.426694:0.287470:0.426694:0.006639:0.010660:0.007466:0.005330
five years of hor-:@0.318912:0.442450:0.475757:0.442450:0.475757:0.426694:0.318912:0.426694:0.004686:0.004686:0.010660:0.012508:0.006642:0.010314:0.012508:0.013143:0.005792:0.007466:0.006644:0.012604:0.006042:0.006639:0.011738:0.012604:0.005782:0.006388
monal blockade with tamoxifen. There :@0.084848:0.459026:0.481089:0.459018:0.481089:0.443262:0.084848:0.443270:0.018049:0.012604:0.011738:0.013143:0.003848:0.011392:0.013123:0.003848:0.012604:0.012450:0.009660:0.013143:0.013181:0.012508:0.011392:0.015990:0.003848:0.006523:0.011738:0.011392:0.006523:0.013143:0.018049:0.012604:0.009236:0.003848:0.006042:0.012508:0.011738:0.005330:0.019063:0.008197:0.011738:0.012508:0.005703:0.012508:0.334041
11 :@0.406030:0.453399:0.421567:0.453399:0.421567:0.444214:0.406030:0.444214:0.006215:0.006215:0.003107
have been conflicting data on 10 years of :@0.084841:0.475594:0.481094:0.475594:0.481094:0.459838:0.084841:0.459838:0.011738:0.013143:0.010660:0.012508:0.005143:0.013123:0.012508:0.012508:0.011738:0.005138:0.012450:0.012604:0.011738:0.004666:0.004666:0.003848:0.012450:0.006523:0.003848:0.011738:0.012950:0.005138:0.013181:0.013143:0.006523:0.013143:0.005145:0.012604:0.011738:0.005140:0.010660:0.010660:0.005149:0.010314:0.012508:0.013143:0.005792:0.007466:0.005143:0.012604:0.006042:0.005330
aromatase inhibition.:@0.084841:0.492171:0.280652:0.492171:0.280652:0.476415:0.084841:0.476415:0.013143:0.005715:0.012604:0.018049:0.013143:0.006523:0.013143:0.007466:0.012508:0.005330:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330
RADIATION:@0.084848:0.525635:0.198592:0.525635:0.198592:0.507820:0.084848:0.507820:0.012401:0.015822:0.014966:0.005987:0.015822:0.008980:0.005987:0.017960:0.015822
The indications for postoperative radiation :@0.084848:0.543356:0.481088:0.543356:0.481088:0.527600:0.084848:0.527600:0.008197:0.011738:0.012508:0.004849:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.004849:0.006042:0.012604:0.005792:0.004849:0.013123:0.012604:0.007466:0.006523:0.012604:0.013123:0.012508:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.004849:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
are a tumour size of 5 cm or more, positive :@0.084848:0.559932:0.481053:0.559932:0.481053:0.544176:0.084848:0.544176:0.013143:0.005715:0.012508:0.005003:0.013143:0.005003:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.004993:0.007466:0.003848:0.008178:0.012508:0.005003:0.012604:0.006042:0.005003:0.010660:0.005003:0.012450:0.018049:0.005003:0.012604:0.005792:0.005003:0.018049:0.012604:0.005709:0.012508:0.005330:0.005003:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.005330
axillary nodes (including patients with 1-3 :@0.084848:0.576508:0.481080:0.576508:0.481080:0.560752:0.084848:0.560752:0.013143:0.009236:0.003848:0.003848:0.003848:0.013143:0.005792:0.010314:0.007439:0.011738:0.012604:0.013181:0.012508:0.007466:0.007428:0.007100:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.007428:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007428:0.015990:0.003848:0.006523:0.011738:0.007428:0.010660:0.006388:0.010660:0.005330
positive  nodes), and patients who have :@0.084848:0.593084:0.481080:0.593084:0.481080:0.577328:0.084848:0.577328:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.005330:0.004495:0.011738:0.012604:0.013181:0.012508:0.007466:0.007100:0.005330:0.009814:0.013143:0.011738:0.013181:0.009814:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009814:0.015990:0.011738:0.012604:0.009814:0.011738:0.013143:0.010660:0.012508:0.005330
undergone a lumpectomy.:@0.084848:0.609660:0.337867:0.609660:0.337867:0.593904:0.084848:0.593904:0.011699:0.011738:0.013181:0.012508:0.005792:0.012950:0.012604:0.011738:0.012508:0.005330:0.013143:0.005330:0.003848:0.011699:0.018049:0.013123:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.005330
Radiation can be omitted  in elderly :@0.103032:0.626236:0.481113:0.626236:0.481113:0.610480:0.103032:0.610480:0.011680:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.013855:0.012450:0.013143:0.011738:0.013855:0.013123:0.012508:0.013855:0.012604:0.018049:0.003848:0.006523:0.006523:0.012508:0.013181:0.005330:0.008511:0.003848:0.011738:0.013855:0.012508:0.003848:0.013181:0.012508:0.005792:0.003848:0.010314:0.005330
women (over 70) following a lumpectomy :@0.084848:0.642812:0.481084:0.642812:0.481084:0.627056:0.084848:0.627056:0.015990:0.012604:0.018049:0.012508:0.011738:0.005426:0.007100:0.012604:0.010660:0.012508:0.005792:0.005426:0.010660:0.010660:0.007100:0.005442:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005426:0.013143:0.005426:0.003848:0.011699:0.018049:0.013123:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.005330
for a small luminal A-like cancer.:@0.084848:0.659389:0.384095:0.659389:0.384095:0.643633:0.084848:0.643633:0.006042:0.012604:0.005792:0.005330:0.013143:0.005330:0.007466:0.018049:0.013143:0.003848:0.003848:0.005330:0.003848:0.011699:0.018049:0.003848:0.011738:0.013143:0.003848:0.005330:0.014239:0.006388:0.003848:0.003848:0.009660:0.012508:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.004376:0.005330
TREATMENT OF METASTATIC  :@0.084848:0.693164:0.400866:0.693164:0.400866:0.673567:0.084848:0.673567:0.009878:0.013641:0.012230:0.017404:0.009878:0.021167:0.012230:0.017404:0.009878:0.006585:0.019756:0.011289:0.006585:0.021167:0.012230:0.009878:0.017404:0.012230:0.009878:0.017404:0.009878:0.006585:0.018344:0.006515:0.006585
BREAST CANCER:@0.084848:0.712680:0.267822:0.712680:0.267822:0.693083:0.084848:0.693083:0.013641:0.013641:0.012230:0.017404:0.012230:0.009878:0.006585:0.018344:0.017404:0.017404:0.018344:0.012230:0.013641
The median survival for metastatic breast :@0.084848:0.731543:0.481082:0.731543:0.481082:0.715787:0.084848:0.715787:0.008197:0.011738:0.012508:0.007149:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.007158:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.007172:0.006042:0.012604:0.005792:0.007149:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.007158:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330
cancer is two to three years, with 25% of :@0.084848:0.748119:0.481107:0.748119:0.481107:0.732364:0.084848:0.732364:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007589:0.003848:0.007466:0.007601:0.006523:0.015990:0.012604:0.007591:0.006523:0.012604:0.007591:0.006523:0.011738:0.005707:0.012508:0.012508:0.007601:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.007601:0.015990:0.003848:0.006523:0.011738:0.007601:0.010660:0.010660:0.014913:0.007601:0.012604:0.006042:0.005330
patients being alive at five years. The in-:@0.084848:0.764696:0.475754:0.764696:0.475754:0.748940:0.084848:0.748940:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008099:0.013123:0.012508:0.003848:0.011738:0.012950:0.008097:0.013143:0.003848:0.003848:0.010660:0.012508:0.008109:0.013143:0.006523:0.008099:0.004686:0.004686:0.010660:0.012508:0.008095:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.008095:0.008197:0.011738:0.012508:0.008090:0.003848:0.011738:0.006388
tention of treatment is to increase survival :@0.084848:0.781272:0.481076:0.781272:0.481076:0.765516:0.084848:0.765516:0.006523:0.012508:0.011738:0.006523:0.003848:0.012604:0.011738:0.006100:0.012604:0.006042:0.006100:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006100:0.003848:0.007466:0.006113:0.006523:0.012604:0.006100:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.006100:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
with a good quality of life. The choice of :@0.084848:0.797848:0.481117:0.797848:0.481117:0.782092:0.084848:0.782092:0.015990:0.003848:0.006523:0.011738:0.007370:0.013143:0.007370:0.012950:0.012604:0.012604:0.013181:0.007360:0.013123:0.011699:0.013143:0.003848:0.003848:0.006523:0.010314:0.007370:0.012604:0.006042:0.007370:0.003848:0.003848:0.006042:0.012508:0.005330:0.007370:0.008197:0.011738:0.012508:0.007370:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.007370:0.012604:0.006042:0.005330
treatment  depends  on  disease  biology, :@0.084848:0.814424:0.481078:0.814424:0.481078:0.798668:0.084848:0.798668:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005886:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.007466:0.005330:0.005896:0.012604:0.011738:0.005330:0.005888:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005898:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.010314:0.005330:0.005330
patient factors, tumour  burden  (includ-:@0.084848:0.831000:0.475764:0.831000:0.475764:0.815244:0.084848:0.815244:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.012411:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.012411:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.007062:0.013123:0.011699:0.005673:0.013181:0.012508:0.011738:0.005330:0.007072:0.007100:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.006388
ing the presence or absence of a visceral :@0.084848:0.847285:0.481094:0.847285:0.481094:0.831529:0.084848:0.831529:0.003848:0.011738:0.012950:0.005830:0.006523:0.011738:0.012508:0.005817:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.005819:0.012604:0.005792:0.005815:0.013143:0.013123:0.007466:0.012508:0.011738:0.012450:0.012508:0.005830:0.012604:0.006042:0.005819:0.013143:0.005830:0.010660:0.003848:0.007466:0.012450:0.012508:0.005792:0.013143:0.003848:0.005330
crisis), previous treatment, and the rate of :@0.084848:0.863570:0.481084:0.863570:0.481084:0.847814:0.084848:0.847814:0.012450:0.005792:0.003848:0.007466:0.003848:0.007466:0.007100:0.005330:0.006004:0.013123:0.005713:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.006004:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005988:0.013143:0.011738:0.013181:0.006004:0.006523:0.011738:0.012508:0.005994:0.005792:0.013143:0.006523:0.012508:0.005994:0.012604:0.006042:0.005330
disease progression (see Table 2). Patients :@0.084848:0.879856:0.481098:0.879856:0.481098:0.864100:0.084848:0.864100:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005888:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005888:0.007100:0.007466:0.012508:0.012508:0.005888:0.007197:0.013143:0.013123:0.003848:0.012508:0.005888:0.010660:0.007100:0.005330:0.005888:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with a visceral crisis should be treated with :@0.084848:0.896141:0.481101:0.896141:0.481101:0.880385:0.084848:0.880385:0.015990:0.003848:0.006523:0.011738:0.004965:0.013143:0.004965:0.010660:0.003848:0.007466:0.012450:0.012508:0.005792:0.013143:0.003848:0.004965:0.012450:0.005792:0.003848:0.007466:0.003848:0.007466:0.004965:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.004955:0.013123:0.012508:0.004965:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.004955:0.015990:0.003848:0.006523:0.011738:0.005330
combination  chemotherapy,  provided :@0.084848:0.912426:0.481084:0.912426:0.481084:0.896670:0.084848:0.896670:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.014974:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010300:0.005330:0.005330:0.014974:0.013123:0.005717:0.012604:0.010660:0.003848:0.013181:0.012508:0.013181:0.005330
that their performance status permits.:@0.084848:0.928711:0.435664:0.928711:0.435664:0.912955:0.084848:0.912955:0.006523:0.011738:0.013143:0.006523:0.005330:0.006523:0.011738:0.012508:0.003848:0.005792:0.005330:0.013123:0.012508:0.006691:0.006042:0.012604:0.006319:0.018049:0.013143:0.011738:0.012450:0.012508:0.005330:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.005330:0.013123:0.012508:0.006317:0.018049:0.003848:0.006523:0.007466:0.005330
According to the ABC3 guidelines, visceral :@0.524249:0.533066:0.920477:0.533066:0.920477:0.517310:0.524249:0.517310:0.014239:0.012450:0.012450:0.012604:0.005665:0.013181:0.003848:0.011738:0.012950:0.004330:0.006523:0.012604:0.004330:0.006523:0.011738:0.012508:0.004330:0.014239:0.011045:0.015644:0.010660:0.004330:0.012950:0.011699:0.003848:0.013181:0.012508:0.003848:0.003848:0.011738:0.012508:0.007466:0.005330:0.004330:0.010660:0.003848:0.007466:0.012450:0.012508:0.005792:0.013143:0.003848:0.005330
crisis is defined as “severe organ dysfunc-:@0.524249:0.549550:0.915166:0.549550:0.915166:0.533794:0.524249:0.533794:0.012450:0.005792:0.003848:0.007466:0.003848:0.007466:0.006523:0.003848:0.007466:0.006519:0.013181:0.012508:0.004686:0.004686:0.011738:0.012508:0.013181:0.006514:0.013143:0.007466:0.006517:0.009660:0.007466:0.012508:0.010660:0.012508:0.005717:0.012508:0.006510:0.012604:0.005804:0.012950:0.013143:0.011738:0.006512:0.013181:0.010314:0.007466:0.006042:0.011699:0.011738:0.012450:0.006388
tion as assessed by signs and symptoms, :@0.524249:0.566033:0.920461:0.566033:0.920461:0.550277:0.524249:0.550277:0.006523:0.003848:0.012604:0.011738:0.008409:0.013143:0.007466:0.008409:0.013143:0.007466:0.007466:0.012508:0.007466:0.007466:0.012519:0.013181:0.008409:0.013123:0.010314:0.008409:0.007466:0.003848:0.012950:0.011738:0.007466:0.008409:0.013143:0.011738:0.013181:0.008409:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.007466:0.005330:0.005330
laboratory studies, and rapid progression :@0.524249:0.582517:0.920461:0.582517:0.920461:0.566761:0.524249:0.566761:0.003848:0.013143:0.013123:0.012604:0.005792:0.013143:0.006523:0.012604:0.005792:0.010314:0.008274:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005330:0.008274:0.013143:0.011738:0.013181:0.008274:0.005792:0.013143:0.013123:0.003848:0.013181:0.008274:0.013123:0.005715:0.012604:0.012950:0.005707:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330
of disease. Visceral crisis is not the mere :@0.524249:0.599000:0.920484:0.599000:0.920484:0.583244:0.524249:0.583244:0.012604:0.006042:0.008794:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.008794:0.013604:0.003848:0.007466:0.012450:0.012508:0.005792:0.013143:0.003848:0.008794:0.012450:0.005792:0.003848:0.007466:0.003848:0.007466:0.008794:0.003848:0.007466:0.008794:0.011738:0.012604:0.006523:0.008794:0.006523:0.011738:0.012508:0.008794:0.018049:0.012508:0.005711:0.012508:0.005330
presence  of  visceral metastases,  but  im-:@0.524249:0.615484:0.915158:0.615484:0.915158:0.599728:0.524249:0.599728:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330:0.003619:0.012604:0.006042:0.005330:0.003619:0.010660:0.003848:0.007466:0.012450:0.012508:0.005792:0.013143:0.003848:0.008967:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.005330:0.003627:0.013123:0.011699:0.006523:0.005330:0.003623:0.003848:0.018049:0.006388
plies important visceral compromise lead-:@0.524249:0.631967:0.915148:0.631967:0.915148:0.616211:0.524249:0.616211:0.013123:0.003848:0.003848:0.012508:0.007466:0.005900:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006512:0.005888:0.010660:0.003848:0.007466:0.012450:0.012508:0.005792:0.013143:0.003848:0.005900:0.012450:0.012604:0.018049:0.013123:0.005713:0.012604:0.018049:0.003848:0.007466:0.012508:0.005888:0.003848:0.012508:0.013143:0.013181:0.006388
ing to a clinical indication for a more rap-:@0.524249:0.648451:0.915141:0.648451:0.915141:0.632695:0.524249:0.632695:0.003848:0.011738:0.012950:0.005888:0.006523:0.012604:0.005888:0.013143:0.005888:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005888:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005888:0.006042:0.012604:0.005792:0.005879:0.013143:0.005888:0.018049:0.012604:0.005707:0.012508:0.005888:0.005792:0.013143:0.013123:0.006388
idly efficacious therapy, particularly since :@0.524249:0.664934:0.920486:0.664934:0.920486:0.649179:0.524249:0.649179:0.003848:0.013181:0.003848:0.010314:0.007041:0.012508:0.006042:0.004686:0.004686:0.012450:0.013143:0.012450:0.003848:0.012604:0.011699:0.007466:0.007031:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.007023:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.003848:0.010314:0.007035:0.007466:0.003848:0.011738:0.012450:0.012508:0.005330
another  treatment  option  at  progression :@0.524249:0.681418:0.920490:0.681418:0.920490:0.665662:0.524249:0.665662:0.013143:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.005330:0.004114:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.004124:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.005330:0.004122:0.013143:0.006523:0.005330:0.004127:0.013123:0.005715:0.012604:0.012950:0.005707:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330
will probably not be possible.”:@0.524249:0.697902:0.803235:0.697902:0.803235:0.682146:0.524249:0.682146:0.015990:0.003848:0.003848:0.003848:0.005330:0.013123:0.005725:0.012604:0.013123:0.013143:0.013123:0.003848:0.010314:0.005330:0.011738:0.012604:0.006523:0.005330:0.013123:0.012508:0.005330:0.013123:0.012604:0.007466:0.007466:0.003848:0.013123:0.003848:0.012508:0.005330:0.009313
The  first-line  treatment  for  endocrine-:@0.542433:0.714385:0.915179:0.714385:0.915179:0.698629:0.542433:0.698629:0.008197:0.011738:0.012508:0.005330:0.007768:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330:0.007782:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.007768:0.006042:0.012604:0.005792:0.005330:0.007766:0.012508:0.011738:0.013181:0.012604:0.012450:0.005792:0.003848:0.011738:0.012508:0.006388
responsive metastatic breast  cancer  is :@0.524249:0.730869:0.920492:0.730869:0.920492:0.715113:0.524249:0.715113:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.003848:0.010660:0.012508:0.013816:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.013816:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330:0.008472:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.008467:0.003848:0.007466:0.005330
therefore hormonal blockade, and chem-:@0.524249:0.747352:0.915183:0.747352:0.915183:0.731596:0.524249:0.731596:0.006523:0.011738:0.012508:0.005705:0.012508:0.006042:0.012604:0.005705:0.012508:0.005003:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.013143:0.003848:0.005003:0.013123:0.003848:0.012604:0.012450:0.009660:0.013143:0.013181:0.012508:0.005330:0.005003:0.013143:0.011738:0.013181:0.005003:0.012450:0.011738:0.012508:0.018049:0.006388
otherapy should be considered only once :@0.524249:0.763836:0.920498:0.763836:0.920498:0.748080:0.524249:0.748080:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005195:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005205:0.013123:0.012508:0.005203:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005713:0.012508:0.013181:0.005201:0.012604:0.011738:0.003848:0.010314:0.005203:0.012604:0.011738:0.012450:0.012508:0.005330
the hormonal-blockade treatment op-:@0.524249:0.780319:0.915158:0.780319:0.915158:0.764563:0.524249:0.764563:0.006523:0.011738:0.012508:0.015952:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.013143:0.003848:0.006388:0.013123:0.003848:0.012604:0.012450:0.009660:0.013143:0.013181:0.012508:0.015952:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.015952:0.012604:0.013123:0.006388
tions have been exhausted. It is important :@0.524249:0.796803:0.920488:0.796803:0.920488:0.781047:0.524249:0.781047:0.006523:0.003848:0.012604:0.011738:0.007466:0.005657:0.011738:0.013143:0.010660:0.012508:0.005657:0.013123:0.012508:0.012508:0.011738:0.005657:0.012508:0.009236:0.011738:0.013143:0.011699:0.007466:0.006523:0.012508:0.013181:0.005330:0.005657:0.004349:0.006523:0.005657:0.003848:0.007466:0.005657:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.005330
to emphasise that the presence of meta-:@0.524249:0.813286:0.915166:0.813286:0.915166:0.797530:0.524249:0.797530:0.006523:0.012604:0.006658:0.012508:0.018049:0.013123:0.011738:0.013143:0.007466:0.003848:0.007466:0.012508:0.006677:0.006523:0.011738:0.013143:0.006523:0.006662:0.006523:0.011738:0.012508:0.006656:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.006662:0.012604:0.006042:0.006660:0.018049:0.012508:0.006523:0.013143:0.006388
static disease is not an indication for sys-:@0.524249:0.829770:0.915148:0.829770:0.915148:0.814014:0.524249:0.814014:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.007832:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.007832:0.003848:0.007466:0.007832:0.011738:0.012604:0.006523:0.007814:0.013143:0.011738:0.007832:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007818:0.006042:0.012604:0.005792:0.007814:0.007466:0.010314:0.007466:0.006388
temic chemotherapy.:@0.524249:0.846253:0.728776:0.846253:0.728776:0.830497:0.524249:0.830497:0.006523:0.012508:0.018049:0.003848:0.012450:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
A  new  class  of  drugs,  CDK  4/6  inhibitors, :@0.542433:0.862737:0.920494:0.862737:0.920494:0.846981:0.542433:0.846981:0.013662:0.005330:0.003375:0.011161:0.011930:0.015413:0.005330:0.003377:0.011873:0.003271:0.012565:0.006889:0.006889:0.005330:0.003377:0.012027:0.005465:0.005330:0.003377:0.012604:0.005215:0.011122:0.012373:0.006889:0.004753:0.005330:0.003377:0.015067:0.013739:0.010795:0.005330:0.003377:0.010083:0.007832:0.010083:0.005330:0.003377:0.003271:0.011161:0.011161:0.003271:0.012546:0.003271:0.005946:0.012027:0.005215:0.006889:0.005328:0.005330
has received regulatory approval in com-:@0.524249:0.879221:0.915129:0.879221:0.915129:0.863465:0.524249:0.863465:0.011161:0.012565:0.006889:0.009852:0.005134:0.011930:0.011873:0.011930:0.003271:0.010083:0.011930:0.012604:0.009852:0.005134:0.011930:0.012373:0.011122:0.003271:0.012565:0.005946:0.012027:0.005215:0.009737:0.009852:0.012565:0.012546:0.012546:0.005136:0.012027:0.010083:0.012565:0.003271:0.009852:0.003271:0.011161:0.009852:0.011873:0.012027:0.017472:0.006388
bination with aromatase inhibitors in first-line :@0.524249:0.895704:0.920484:0.895704:0.920484:0.879948:0.524249:0.879948:0.012546:0.003271:0.011161:0.012565:0.005946:0.003271:0.012027:0.011161:0.006804:0.015413:0.003271:0.005946:0.011161:0.006804:0.012565:0.005136:0.012027:0.017472:0.012565:0.005946:0.012565:0.006889:0.011930:0.006804:0.003271:0.011161:0.011161:0.003271:0.012546:0.003271:0.005946:0.012027:0.005215:0.006889:0.006804:0.003271:0.011161:0.006804:0.004397:0.004397:0.005215:0.006889:0.005946:0.005811:0.003271:0.003271:0.011161:0.012506:0.005330
metastatic breast cancer, or with fulves-:@0.524249:0.912188:0.915189:0.912188:0.915189:0.896432:0.524249:0.896432:0.017472:0.011930:0.005946:0.012565:0.006889:0.005946:0.012565:0.005946:0.003271:0.011873:0.013200:0.012546:0.005134:0.011930:0.012565:0.006889:0.005946:0.013200:0.011873:0.012565:0.011161:0.011873:0.011930:0.003190:0.004753:0.013200:0.012027:0.005215:0.013200:0.015413:0.003271:0.005946:0.011161:0.013200:0.005465:0.011122:0.003271:0.010083:0.011930:0.006889:0.006388
trant, an anti-oestrogen that downregulates :@0.524249:0.928671:0.920559:0.928671:0.920559:0.912915:0.524249:0.912915:0.005946:0.005215:0.012565:0.011161:0.005946:0.004753:0.006235:0.012565:0.011161:0.006235:0.012565:0.011161:0.005946:0.003271:0.005811:0.012027:0.011930:0.006889:0.005946:0.005134:0.012027:0.012373:0.011930:0.011161:0.006235:0.005946:0.011161:0.012565:0.005946:0.006235:0.012604:0.012027:0.015413:0.011161:0.005134:0.011930:0.012373:0.011122:0.003271:0.012565:0.005946:0.011930:0.007468:0.005330
Table 2. Factors determining choice  :@0.524249:0.096173:0.860971:0.096173:0.860971:0.080139:0.524249:0.080139:0.007889:0.012508:0.012508:0.004426:0.012123:0.005195:0.010583:0.005195:0.005195:0.009044:0.012508:0.012123:0.005580:0.012123:0.005965:0.008274:0.005195:0.012508:0.012123:0.005580:0.012123:0.005965:0.017895:0.004426:0.011353:0.004426:0.011353:0.012508:0.005195:0.012123:0.011353:0.012123:0.004426:0.012123:0.012317:0.004982:0.005388
of treatment in ABC:@0.524249:0.112339:0.701664:0.112339:0.701664:0.096305:0.524249:0.096305:0.012123:0.005195:0.005195:0.005580:0.005965:0.012123:0.012508:0.005580:0.017895:0.012123:0.011353:0.005580:0.005195:0.004426:0.011353:0.005195:0.014047:0.010968:0.015009
Disease :@0.533867:0.143087:0.610454:0.143087:0.610454:0.127053:0.533867:0.127053:0.013277:0.004426:0.008274:0.012123:0.012508:0.008274:0.012317:0.005388
characteristics:@0.533867:0.159253:0.667410:0.159253:0.667410:0.143219:0.533867:0.143219:0.012123:0.011353:0.012508:0.005965:0.012508:0.012123:0.005580:0.012123:0.005965:0.004426:0.008274:0.005580:0.004426:0.012123:0.008467
Patient :@0.728793:0.143087:0.796522:0.143087:0.796522:0.127053:0.728793:0.127053:0.010583:0.012508:0.005580:0.004426:0.012123:0.011353:0.005769:0.005388
characteristics:@0.728793:0.159253:0.862335:0.159253:0.862335:0.143219:0.728793:0.143219:0.012123:0.011353:0.012508:0.005965:0.012508:0.012123:0.005580:0.012123:0.005965:0.004426:0.008274:0.005580:0.004426:0.012123:0.008467
Prior adjuvant :@0.533867:0.181676:0.667948:0.181676:0.667948:0.165920:0.533867:0.165920:0.011392:0.005792:0.003848:0.012604:0.005792:0.005330:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330
chemotherapy:@0.533867:0.197842:0.674356:0.197842:0.674356:0.182087:0.533867:0.182087:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
Patient :@0.728793:0.181676:0.799797:0.181676:0.799797:0.165920:0.728793:0.165920:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330
preferences  :@0.728793:0.197842:0.851725:0.197842:0.851725:0.182087:0.728793:0.182087:0.013123:0.005715:0.012508:0.006042:0.012508:0.005707:0.012508:0.011738:0.012450:0.012508:0.007466:0.005330:0.005330
(e.g., oral:@0.728793:0.214009:0.818058:0.214009:0.818058:0.198253:0.728793:0.198253:0.007100:0.012508:0.005330:0.012950:0.005330:0.005330:0.005330:0.012604:0.005792:0.013143:0.003848
 vs :@0.818039:0.214009:0.846826:0.214009:0.846826:0.198253:0.818039:0.198253:0.005330:0.010660:0.007466:0.005330
 :@0.846826:0.214009:0.852156:0.214009:0.852156:0.198253:0.846826:0.198253:0.005330
IV treatment):@0.728793:0.230175:0.852306:0.230175:0.852306:0.214419:0.728793:0.214419:0.004349:0.013508:0.005330:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.007100
Disease burden:@0.533867:0.252598:0.678385:0.252598:0.678385:0.236842:0.533867:0.236842:0.014316:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.011699:0.005684:0.013181:0.012508:0.011738
Socio-economic :@0.728793:0.252598:0.887851:0.252598:0.887851:0.236842:0.728793:0.236842:0.009583:0.012604:0.012450:0.003848:0.012604:0.006388:0.012508:0.012450:0.012604:0.011738:0.012604:0.018049:0.003848:0.012450:0.005330
and psychological :@0.728793:0.268764:0.907901:0.268764:0.907901:0.253008:0.728793:0.253008:0.013143:0.011738:0.013181:0.005330:0.013123:0.007466:0.010314:0.012450:0.011738:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005330
factors (e.g., :@0.728793:0.284930:0.852021:0.284930:0.852021:0.269174:0.728793:0.269174:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.007100:0.012508:0.005330:0.012950:0.005330:0.005330:0.005330
distance between :@0.728793:0.301096:0.905207:0.301096:0.905207:0.285340:0.728793:0.285340:0.013181:0.003848:0.007466:0.006523:0.013143:0.011738:0.012450:0.012508:0.005330:0.013123:0.012508:0.006523:0.015990:0.012508:0.012508:0.011738:0.005330
home and :@0.728793:0.317262:0.832413:0.317262:0.832413:0.301506:0.728793:0.301506:0.011738:0.012604:0.018049:0.012508:0.005330:0.013143:0.011738:0.013181:0.005330
hospital; costs):@0.728793:0.333428:0.865356:0.333428:0.865356:0.317672:0.728793:0.317672:0.011738:0.012604:0.007466:0.013123:0.003848:0.006523:0.013143:0.003848:0.005330:0.005330:0.012450:0.012604:0.007466:0.006523:0.007466:0.007100
Prior therapies and  Age, PS, :@0.533867:0.355852:0.810785:0.355852:0.810785:0.340096:0.533867:0.340096:0.011392:0.005792:0.003848:0.012604:0.005792:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.007466:0.005330:0.013143:0.011738:0.013181:0.005330:0.014797:0.014239:0.012950:0.012508:0.005330:0.005330:0.011392:0.009583:0.005330:0.005330
response:@0.533867:0.372018:0.616993:0.372018:0.616993:0.356262:0.533867:0.356262:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508
comorbidities:@0.728793:0.372018:0.854638:0.372018:0.854638:0.356262:0.728793:0.356262:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.003848:0.012508:0.007466
Aggressiveness of :@0.533867:0.394441:0.702648:0.394441:0.702648:0.378685:0.533867:0.378685:0.014239:0.012950:0.012950:0.005702:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.011738:0.012508:0.007466:0.007466:0.005330:0.012604:0.006042:0.005330
disease:@0.533867:0.410607:0.603987:0.410607:0.603987:0.394851:0.533867:0.394851:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508
Menopausal status:@0.728793:0.394441:0.903899:0.394441:0.903899:0.378685:0.728793:0.378685:0.017684:0.012508:0.011738:0.012604:0.013123:0.013143:0.011699:0.007466:0.013143:0.003848:0.005330:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466
ER/PgR, HER2 :@0.533867:0.433031:0.662079:0.433031:0.662079:0.417275:0.533867:0.417275:0.010314:0.011680:0.008409:0.011392:0.012950:0.011680:0.005330:0.005330:0.013143:0.010314:0.011680:0.010660:0.005330
receptor status:@0.533867:0.449197:0.673238:0.449197:0.673238:0.433441:0.533867:0.433441:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466
Disease-free :@0.533867:0.471620:0.653622:0.471620:0.653622:0.455864:0.533867:0.455864:0.014316:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.006388:0.006042:0.005725:0.012508:0.012508:0.005330
interval:@0.533867:0.487786:0.601928:0.487786:0.601928:0.472030:0.533867:0.472030:0.003848:0.011738:0.006523:0.012508:0.005792:0.010660:0.013143:0.003848